The Europe Parkinson’s Disease Treatment market size stood at around USD 1.4 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Parkinson’s disease is a chronic, degenerative disorder of the motor nervous system. The disease is slow to develop and initial symptoms include rigidity, shaking, difficulty to walk followed by behavioral problems later. Dr. Bastiaan Bloem, a Dutch neurologist warns of an upcoming Parkinson’s pandemic, in which he says that the number of people suffering from Parkinson’s disease will double in the next 20 years. He believes this is due to exposure to chemicals such as herbicides, solvents etc.
In Netherlands, the expenditure on care for Parkinson’s disease and other forms of Parkinsonism amounted to 204.1 million euros in 2017. This corresponds to 0.23% of the total health care expenditure in the Netherlands. Out of this, 45% was attributable to the elderly care sector. In addition, 19% went to medicines and aids, 18% to primary care and 14% to hospital care.
The market is expected to be driven by the high prevalence of Parkinson’s disease. According to statistics, In 2019, an estimated 52,900 people were diagnosed with parkinsonism. This corresponds to 3.7 per 1,000 men and 2.5 per 1,000 women. This concerns all forms of Parkinsonism, of which Parkinson’s disease is the main group. The higher prevalence is also attributed to the large old age population.
There is increased importance on research and development in the area of Parkinson’s disease which is favourable to market growth.
The presence of skilled professionals also drives the market.